

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/066882 A1

(51) International Patent Classification:

A61K 31/7072 (2006.01) A61K 45/00 (2006.01)
A61K 31/7088 (2006.01) A61K 45/06 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/051718

(22) International Filing Date:

23 September 2021 (23.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/082,207	23 September 2020 (23.09.2020)	US
63/165,270	24 March 2021 (24.03.2021)	US
63/178,379	22 April 2021 (22.04.2021)	US
63/184,051	04 May 2021 (04.05.2021)	US

(71) Applicant: **ONCOLINEA PHARMACEUTICALS, INC.** [US/US]; 2765 Sand Hill Road, Menlo Park, California 94025 (US).

(72) Inventor: **WEBER, Eckard**; 4040 Miller Street, San Diego, California 92103 (US).

(74) Agent: **ESMOND, Robert W.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR




FIG. 3

(57) Abstract: Disclosed is a method for treating cancer in patient in need thereof comprising administering a therapeutically effective amount of a reverse transcriptase inhibitor (RTI) to the patient according to a continuous or an intermittent dosing schedule. RTIs include, but are not limited to, lamivudine (3TC), stavudine (d4T), emtricitabine (FTC), abacavir (ABC), tenofovir alafenamide, zidovudine (AZT), zalcitabine (ddC), didanosine (ddI), tenofovir disoproxil, adefovir dipivoxil, entecavir (ETV), telbivudine, censavudine, and islatravir.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*